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BRCA1/2 proteins function in homologous recom-
bination (HR)-mediated DNA repair and cooperate
with Fanconi anemia (FA) proteins to maintain ge-
nomic integrity through replication fork stabilization.
Loss of BRCA1/2 proteins results in DNA repair defi-
ciency and replicative stress, leading to genomic
instability and enhanced sensitivity to DNA-damaging
agents. Recent studies have shown that BRCA1/2-
deficient tumors upregulate Polq-mediated alterna-
tive end-joining (alt-EJ) repair as a survival mecha-
nism. Whether other mechanisms maintain genomic
integrity upon loss of BRCA1/2 proteins is currently
unknown. Here we show that BRCA1/2-deficient
tumors also upregulate FANCD2 activity. FANCD2
is required for fork protection and fork restart in
BRCA1/2-deficient tumors. Moreover, FANCD2 pro-
motes Polq recruitment at sites of damage and alt-
EJ repair. Finally, loss of FANCD2 in BRCA1/2-defi-
cient tumors enhances cell death. These results reveal
a synthetic lethal relationship between FANCD2 and
BRCA1/2, and they identify FANCD2 as a central
player orchestrating DNA repair pathway choice at
the replication fork.INTRODUCTION
Multiple mechanisms cooperate in cells to ensure the fidelity of
DNA replication and to maintain genome integrity. Exogenous
DNA damage and/or endogenous replication stress cause stall-
ing of replication forks, leading to the recruitment of multiple pro-
teins that stabilize stalled forks, repair DNA lesions, and restart
replication (Branzei and Foiani, 2007, 2010; Michel et al.,
2004). Failure to arrest replication forks at damaged sites or to
restart replication once the repair is completed affects both
genomic stability and cell survival (Cox et al., 2000). Indeed,
damaged DNA, such as double-strand breaks (DSBs) and inter-2488 Cell Reports 15, 2488–2499, June 14, 2016 ª 2016 The Author(
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main forces that drive genome instability (Aparicio et al., 2014;
Deans and West, 2011).
BRCA1 and BRCA2 (BRCA1/2) proteins have a dual role in
protecting genomic integrity. On the one hand, BRCA1/2 pro-
teins promote homologous recombination (HR)-mediated DNA
repair (Moynahan et al., 1999, 2001). On the other hand, these
proteins also limit replication stress by controlling the stability
of stalled replication forks (Lomonosov et al., 2003; Pathania
et al., 2014; Schlacher et al., 2011; Willis et al., 2014). Another
DNA repair pathway carrying repair-independent functions dur-
ing replication is the Fanconi anemia (FA) pathway (Gari et al.,
2008; Kim and D’Andrea, 2012). Indeed, BRCA1/2 and some
FA proteins, such as FANCD2, localize to stalled replication
forks, protect nascent strands from excessive nucleolytic degra-
dation (Lossaint et al., 2013; Schlacher et al., 2011, 2012), and
facilitate replication restart once DNA repair is complete (Los-
saint et al., 2013; Schwab et al., 2015). For these reasons, the
FA andBRCA1/2 proteins play a central role in limiting replication
stress (Chan et al., 2009; Howlett et al., 2005; Naim and Rosselli,
2009). According to a conventional model, FANCD2 and BRCA1/
2 proteins cooperate in an epistatic pathway, namely the FA/
BRCA pathway, to both repair DNA lesions and stabilize replica-
tion forks (Kim and D’Andrea, 2012).
In accordance with the DNA repair and fork stabilization
functions of BRCA1/2 proteins, BRCA1/2-deficient tumor cells
exhibit both increased genomic instability and replicative stress
(Cancer Genome Atlas Research Network, 2011; Schlacher
et al., 2011; Zeman and Cimprich, 2014). As a result, BRCA1/
2-deficient cells are hypersensitive to chemotherapeutic agents,
such as PARP inhibitors (PARPis) (Bryant et al., 2005; Farmer
et al., 2005; Konstantinopoulos et al., 2015), and to replication
stress-inducing poisons (Howlett et al., 2005).
In BRCA1/2-deficient cells, unstable replication forks lead to
chromosomal translocation and copy number variation (Hast-
ings et al., 2009). Although genomic instability is critical to tumor
progression, its excess can limit cell survival (Bartkova et al.,
2005; Negrini et al., 2010). As a consequence, BRCA1/2-defi-
cient cells have evolved mechanisms to tolerate replication
stress and genomic instability, with the ultimate goal of ensuring
DNA replication and cell survival (Ceccaldi et al., 2016). As ans).
creativecommons.org/licenses/by-nc-nd/4.0/).
example, BRCA1/2-deficient cells upregulate the error-prone
Polq/PARP1-mediated alternative end-joining (alt-EJ) DNA re-
pair pathway, thereby compensating for defective HR (Ceccaldi
et al., 2015; Mateos-Gomez et al., 2015). Polq is a translesion
synthesis polymerase (Yousefzadeh and Wood, 2013) that
prevents RAD51 assembly on single-stranded DNA (Ceccaldi
et al., 2015; Newman et al., 2015), and it concurrently mediates
PARP1-dependent alt-EJ to resume DNA replication (Kent et al.,
2015). As a consequence, BRCA1/2-deficient cells are depen-
dent on alt-EJ for survival. Inhibition of proteins functioning in
alt-EJ, such as PARP1 or Polq, is synthetically lethal in tumors
with inactivated BRCA1/2 (Bryant et al., 2005; Ceccaldi et al.,
2015; Farmer et al., 2005; Mateos-Gomez et al., 2015). Besides
intrinsically promoting tumor cell survival, the hyperactivation of
mechanisms counteracting the onset of genomic instability also
can lead to drug resistance (Bouwman and Jonkers, 2014; Lord
and Ashworth, 2013). For example, secondary intragenic
BRCA1/2mutations can restore enzyme functionality and rescue
HR, thus representing themost common acquiredmechanism of
resistance to cisplatin or PARPi (Edwards et al., 2008; Sakai
et al., 2008).
Despite extensive research on mechanisms conferring resis-
tance to PARPi (Bouwman and Jonkers, 2014; Lord and Ash-
worth, 2013), how BRCA1/2-deficient tumors limit their replica-
tion stress remains unknown. Many DNA repair proteins are
indeed recruited to stalled forks upon replication stress (Alabert
et al., 2014; Sirbu et al., 2013). For instance PARP1, whose func-
tion is required for BRCA1/2-deficient cell survival, is present at
the stalled replication fork and contributes to fork stabilization
and recovery (Bryant et al., 2009; Ying et al., 2012, 2016).
Whether other factors contribute to fork stabilization and survival
of BRCA1/2-deficient cells is currently unknown.
Here we demonstrate that BRCA1/2-deficient tumors exhibit a
compensatory increase in FANCD2 expression and activity.
Upon loss of BRCA1/2 proteins, FANCD2 localizes to stalled
replication forks where it promotes replication fork protection
and restart. FANCD2 recruits Polq and CtIP to stalled forks and
is required for alt-EJ. As a consequence, FANCD2 overexpres-
sion in BRCA1/2 mutant cells confers resistance to PARPi
through replication fork stabilization. Finally, double-knockdown
experiments of FANCD2 and BRCA1/2 lead to tumor cell death
in vitro and in vivo, revealing a synthetic lethal relationship be-
tween these proteins. Our findings identify FANCD2 as a critical
factor required for the viability of BRCA1/2-deficient tumors and
for orchestrating DNA repair pathway choice at replication forks.
RESULTS
FANCD2 Is Upregulated in BRCA1/2-Deficient Cells
To identify gene candidates essential for the survival of BRCA1/
2-deficient tumors, we examined gene expression profiles in
cancers frequently associated with defects in HR (i.e., mutations
in BRCA1/2 genes) (Cancer Genome Atlas Network, 2012;
Cancer Genome Atlas Research Network, 2011). Publicly avail-
able microarray databases revealed specific overexpression of
FANCD2 in subgroups of ovarian, breast, and uterine cancers
associated with HR deficiency and high genomic instability (Fig-
ure 1A). FANCD2 expression was upregulated in a grade-depen-dent manner, correlated with KI67 expression, and increased in
tumors harboring alterations (mutations or epigenetic silencing)
in BRCA1 or BRCA2 (Figures S1A–S1D). Since FANCD2 and
BRCA1/2 proteins are known to function epistatically in DNA
repair and fork protection (Kim and D’Andrea, 2012; Lossaint
et al., 2013; Schlacher et al., 2011, 2012), we analyzed the rela-
tionship between FANCD2 activation and BRCA1/2 alterations.
Knockdown of BRCA1 or BRCA2 (BRCA1/2) with small inter-
fering RNA (siRNA) resulted in increased FANCD2 monoubiquiti-
nation (FANCD2-Ub), similar to the level observed by depletion
of the deubiquitinase enzyme USP1 (Nijman et al., 2005) (Figures
S1E and S1F). Subcellular fractionation of HeLa cells revealed
that BRCA2 depletion increased FANCD2-Ub enrichment on
the chromatin (Figure 1B). Knockdown of BRCA1/2 proteins
increased basal and damage-inducible FANCD2 expression
and foci formation (Figures 1C and S1G–S1I). Taken together,
these data suggest that FANCD2 expression and activation are
increased in the setting of BRCA1/2 deficiency.
FANCD2 Stabilizes Replication Forks in
BRCA1/2-Deficient Cells
Loss of BRCA1/2 hinders fork stability and increases replication
stress (Schlacher et al., 2011). Given that FANCD2 has emerged
recently as a key factor in stabilizing replication forks (Lossaint
et al., 2013; Schlacher et al., 2012) and since we observed a
compensatory increase in FANCD2 activity in cells lacking
BRCA1/2, we tested whether FANCD2 could have a primary
role in stabilizing replication forks in this genetic setting. Two
known replication stress proteins, TopBP1 and PCNA, form nu-
clear foci at sites of halted DNA replication (Howlett et al., 2009;
Yan and Michael, 2009). We found that, in response to hydroxy-
urea (HU)-induced replicative stress, FANCD2 foci colocalize
with TopBP1, similar to what is observed with PCNA foci (Howl-
ett et al., 2009). Interestingly, BRCA2 knockdown increased
FANCD2 colocalization with TopBP1 and PCNA (Figure 1D).
Moreover, siRNA-mediated BRCA1 and BRCA2 depletion in
FANCD2-deficient cells (PD20) caused a significant increase in
fork degradation and fork collapse after fork stalling by HU (Fig-
ures 1E, 1F, S1J, and S1K). To assess the importance of
FANCD2monoubiquitination in the stabilization of the replication
fork in BRCA1/2-deficient cells, we evaluated the ability of wild-
type (WT) or the ubiquitination mutant of FANCD2 (K561R-
FANCD2) to complement the siBRCA1/2-mediated fork insta-
bility. Expression of WT FANCD2 in FANCD2-deficient (PD20)
cells rescued fork degradation and fork restart, while K561R-
FANCD2 did not (Figures 1E, 1F, S1J, and S1K). Collectively,
these data indicate that loss of BRCA1/2 triggers localization
of FANCD2-Ub to stalled replicative sites, where it maintains
fork stability and promotes replication fork restart.
Synthetic Lethal Interaction between BRCA1/2 and
FANCD2
Given that the stability of replication forks is essential for
genomic integrity (Zeman and Cimprich, 2014), we hypothe-
sized that FANCD2 is required for maintaining genomic stability
in BRCA1/2-deficient cells. HR-deficient ovarian tumor cell
lines, A2780-shBRCA1 and A2780-shBRCA2 cells, were gener-
ated and subjected to siRNA-mediated FANCD2 depletion, andCell Reports 15, 2488–2499, June 14, 2016 2489
Figure 1. Upregulated FANCD2 Protects Replication Forks in BRCA2-Deficient Tumor Cells
(A) FANCD2 gene expression in subtypes of ovarian, breast, and uterine cancers. For each tumor group, expression values are represented as the mean of Z
scores.
(B) FANCD2 immunoblot in HeLa cells after siRNA depletion of BRCA2, at indicated time points after UV treatment and cellular fractionation. Immunoblot shows
BRCA2 depletion efficiency.
(C) Quantification of baseline and damage (HU)-induced FANCD2 foci in HeLa cells after siRNA depletion of BRCA2. Representative images are shown. Statistics
were performed on nR 150 cells per condition and expressed as relative to siScr that was conventionally set to 1.
(D) Baseline and damage (HU)-induced FANCD2 TopBP1 and FANCD2PCNA immunofluorescence in HeLa cells after siRNA depletion of BRCA2. Representative
images are shown. Statistics were performed on nR 150 cells per condition and expressed as relative to siScr that was conventionally set to 1.
(E and F) Schematic for the labeling of FANCD2-deficient (PD20) cells with IdU and CldU for fork degradation (E) and for fork restart experiments (F). Scatter dot
plots for CldU to IdU ratio of cells expressing indicated cDNA and transfected with indicated siRNA are shown. Statistics were performed on nR 100 fibers per
condition and expressed as relative to EV that was conventionally set to 1. Representative images are shown.
Data in (C)–(F) represent mean ± SEM over three independent experiments. Data in (A) and (C)–(F) were analyzed using Student’s t test. ON, overnight; ns, non
significant; EV, empty vector; WT, wild-type.clonogenic survival was measured (Figure S2A). FANCD2 deple-
tion reduced the survival of BRCA1/2-deficient cells but had no
effect on the isogenic HR-proficient cells (Figure 2A). Moreover,
tumor cells expressing small hairpin RNAs (shRNAs) against
both BRCA2 and FANCD2 exhibited increased chromosomal
aberrations and reduced survival after Mitomycin C (MMC)
treatment as compared to shScr control cells (Figures 2B, 2C,
and S2B). Consistent with these findings, a BRCA2-depleted
(VU423) cell line showed increased basal and MMC-induced
chromosomal aberrations together with reduced clonogenic sur-
vival after siRNA-mediated FANCD2 depletion (Figures 2D and
S2C). Since FANCD2 forms a heterodimer with FANCI (Smogor-2490 Cell Reports 15, 2488–2499, June 14, 2016zewska et al., 2007), we evaluated the potential synthetic
lethality between FANCI and BRCA1/2 proteins. Similar to
FANCD2, FANCI depletion specifically reduced BRCA1/2-defi-
cient cell survival without affecting the survival of BRCA1/2-pro-
ficient cells (Figures S2D). Collectively, our data show that
FANCD2 limits the extent of genomic instability in BRCA1/2-defi-
cient cells and is required for their survival.
FANCD2 Depletion Reduces Survival of
BRCA1/2-Deficient Tumors In Vitro and In Vivo
To further analyze the synthetic lethal relationship between
FANCD2 and BRCA1/2, we measured the clonogenic survival of
Figure 2. FANCD2 Maintains Genomic Stability in BRCA1- and BRCA2-Deficient Tumors
(A) Clonogenic formation of A2780 cells expressing the indicated shRNA together with the indicated siRNA. Immunoblot showing knockdown efficiencies of
siRNAs and representative images for clonogenic formation are shown.
(B) Chromosome breakage analysis of A2780 cells expressing the indicated shRNA and treated with MMC is shown.
(C) Clonogenic formation of A2780 cells expressing the indicated shRNA under increasing concentrations of MMC. Survival is shown as relative to the untreated
sample (MMC 0 ng/ml). Immunoblot shows silencing efficiency of shRNAs.
(D) Chromosome breakage analysis of BRCA2-deficient (VU 423) cells transfected with the indicated siRNA. Representative images are shown. Arrows indicate
chromosomal aberrations.
Data in (A)–(D) represent mean ±SEM over three independent experiments and were analyzed by using the chi-square test for trend in proportions (A) or Student’s
t test (B and D). Data in (A) and (D) are displayed as relative to siScr samples, while in (B) they are displayed as relative to shBRCA2 sample.a panel of 18 breast and 36 ovarian cell lines (Table S1) subjected
to FANCD2 depletion. Depletion of FANCD2 primarily affected
survival of cell lines with BRCA1/2 alterations (Figures 3A and
S3A). FANCD2 depletion also affected BRCA1-deficient tumor
growth in vivo. The BRCA1-mutated (MDA-MB-436) breast cell
line, expressing a doxycycline-inducible FANCD2 shRNA, was
xenotransplanted into athymic nude mice. Once tumors reached
palpablesizes (100–200mm3),micewere treatedwithdoxycycline
and tumor volumes were measured for 6 weeks. FANCD2 deple-
tion significantly impaired tumor growth in vivo (Figures 3B and
3C). Taken together, these data confirm that BRCA1/2-deficient
tumors are hypersensitive to the loss of FANCD2.
To determinewhether FANCD2monoubiquitination is required
for the survival of BRCA1/2-depleted cells, we performed
complementation studies in BRCA1/2-deficient cells. Expres-
sion of WT, but not K561R-FANCD2, in FANCD2-deficient
(PD20) cells in which BRCA2 had been depleted rescued
clonogenic survival and MMC toxicity (Figures 3D and 3E). Simi-
larly, in BRCA1-mutated (MDA-MB-436) cells in which the
endogenous FANCD2 had been depleted, expression of WT,
but not K561R-FANCD2, rescued clonogenic survival (Fig-
ure S3B). Taken together, our findings indicate that FANCD2monoubiquitination is required to maintain genomic stability
and cell survival in BRCA1/2-deficient tumors.
FANCD2 Is Required for Polq and CtIP Foci Assembly
and Promotes Alt-EJ in BRCA1/2-Deficient Tumors
FANCD2 expression highly correlates with Polq expression (Fig-
ure S4A), an alt-EJ factor strongly upregulated in BRCA1/2-defi-
cient cells (Ceccaldi et al., 2015). Moreover, tumors with high
FANCD2 expression exhibit an increase in point mutation fre-
quency and copy-number alteration, suggesting an increase in
error-prone alt-EJ repair (Figures S4B and S4C). Knockdown
of BRCA2 increased DNA damage-inducible Polq foci formation
(Figure 4A), confirming that alt-EJ activity is upregulated in
BRCA1/2-deficient tumors (Ceccaldi et al., 2015). Recent evi-
dence has suggested a role of FA proteins in alt-EJ (Howard
et al., 2015). Moreover, the FA protein FANCA is required for
class switch recombination (Nguyen et al., 2014), a process
that relies, at least in part, on alt-EJ for rejoining DSBs (Deriano
and Roth, 2013). Nonetheless, the mechanism by which the FA
pathway interacts with alt-EJ remains unknown. In accordance
with previous findings, in a cell-based assay that measures the
efficiency of recombination of two GFP alleles (alt-EJ assay)Cell Reports 15, 2488–2499, June 14, 2016 2491
Figure 3. BRCA1- and BRCA2-Deficient Tumor Cells Are Hyperdependent on Monoubiquitinated FANCD2 for Survival
(A) Clonogenic formation of a panel of 18 breast cell lines transfected with Scr or FANCD2 siRNA. Percentage survival of cells transfected with siFANCD2 versus
siScr is plotted. The genetic status of the cell line analyzed is indicated (Nle, normal, non-transformed mammary epithelial cell line; TNBC, triple negative breast
cancer; HRP, HR-proficient; and HRD, HR-deficient). FANCD2 gene expression in the 58 breast cell lines from the CCLE collection includes 16 of the 18 breast
cell lines tested. Cell lines are grouped based on their genetic status. For each group, expression values are represented as the mean of Z scores. (Hor. pos.,
hormone positive breast cancer). A non-parametric test (Mann-Whitney-Wilcoxon) was used to compare the value of the HRD TNBC group with the rest of the
groups.
(B) Growth of MDA-MB-436 cells expressing doxycycline (dox)-inducible FANCD2 or scrambled (Scr) shRNA in athymic nudemice. Immunoblot shows silencing
efficiency.
(C) Relative tumor volumes (RTVs) for individual mice treated in (B) after 5 weeks of dox treatment. Each group represents nR 10 tumors from nR 6 mice while
each dot represents data from one tumor. Data are shown as mean ±SEM. Student’s t test was used to compare each sample to shFANCD2;dox.
(D) Clonogenic formation of FANCD2-deficient (PD20) cells expressing EV or FANCD2 cDNA constructs and transfected with BRCA2 siRNA. Percentage survival
of cells transfected with BRCA2 versus Scr siRNA is plotted. An immunoblot shows expression of FANCD2 cDNA constructs. Representative images are shown.
(E) Clonogenic formation of FANCD2-deficient (PD20) cells expressing EV or FANCD2 cDNA constructs and transfected with BRCA2 siRNA in increasing
concentrations of MMC. Percentage survival relative to non-treated cells (MMC 0 ng/ml) is plotted.
Data in (A), (D), and (E) represent mean ±SEM over three independent experiments. Data in (D) were analyzed using the chi-square test for trend in proportions.(Bennardo et al., 2008) (Howard et al., 2015), FANCD2 depletion
reduced alt-EJ efficiency similar to the reduction observed
following PARP1 or Polq depletion (Figure 4B). Conversely,
FANCD2 depletion had no effect on single-strand annealing
(SSA), another DSB repair mechanism, thus arguing for a spe-
cific role of FANCD2 in alt-EJ (Figure S4D).
Since FANCD2 and the Polq-mediated alt-EJ pathway are up-
regulated and essential for BRCA1/2-deficient cell survival (Cec-
caldi et al., 2015; Mateos-Gomez et al., 2015), we next evaluated
whether FANCD2 could cooperate with Polq in promoting alt-EJ.
Interestingly, FANCD2 and Polq colocalized at damage foci and
at laser-induced gH2AX-positive DNA breaks (Figures 4C and
4D). The endonuclease CtIP cooperates with BRCA1 to promote
DNA end resection and HR repair at DSBs (Escribano-Dı´az et al.,
2013; Sartori et al., 2007), but it also is required for alt-EJ (Badie
et al., 2015; Zhang and Jasin, 2011). In addition, CtIP and
FANCD2 proteins physically interact (Murina et al., 2014; Unno
et al., 2014; Yeo et al., 2014). Based on these findings, we deter-
mined whether CtIP might cooperate with FANCD2 and Polq in
alt-EJ repair. CtIP, like FANCD2, colocalized with Polq at sites2492 Cell Reports 15, 2488–2499, June 14, 2016of DNA breaks (Figure 4E). We next aimed at better elucidating
the functional hierarchy among these alt-EJ factors. Of note,
FANCD2 inhibition reduced Polq accumulation at laser-induced
DNA breaks and Polq foci (Figures 4F, 4G, and S4E), similar to
the reduction observed upon depletion of the alt-EJ factor
PARP1 (Audebert et al., 2004; Ceccaldi et al., 2015; Mateos-Go-
mez et al., 2015). Analogous to MMC treatment (Murina et al.,
2014), knockdown of FANCD2 impaired UV light- and HU-
induced CtIP foci formation, together with its localization to
laser-induced DNA breaks (Figures S4F and S4G). Knockdown
of Polq did not affect FANCD2 foci formation (Figure S4H), and
depletion of CtIP by siRNA neither affected FANCD2 and Polq
foci formation nor their localization to DNA breaks (Figures S4I
and S4J). Taken together, these data establish a functional hier-
archy among alt-EJ factors, and they suggest that FANCD2
functions upstream of Polq and CtIP in the alt-EJ pathway by
orchestrating their recruitment to sites of DSB repair.
To further dissect how FANCD2 mediates alt-EJ, we asked
whether itsmonoubiquitination is necessary. To this goal, we first
assessed the ability ofWTor K561R-FANCD2 to complement the
Figure 4. Monoubiquitinated FANCD2 Is Required for Polq and CtIP Foci Formation and for Alt-EJ
(A) Quantification of damage (UV)-induced Polq foci in HeLa cells after siRNA depletion of BRCA2 is shown.
(B) EJ reporter assay in EJ2-U2OS cells transfected with the indicated siRNA is shown.
(C) FANCD2 immunofluorescence of HeLa cells transfected with GFP-tagged full-length Polq and subjected to UV damage. Representative images are shown.
(D) FANCD2 and gH2AX immunofluorescence in HeLa cells transfected with GFP-tagged full-length Polq after laser micro-irradiation. Representative images are
shown.
(E) FANCD2 and CtIP immunofluorescence in HeLa cells transfected with GFP-tagged full-length Polq after laser micro-irradiation. Representative images are
shown.
(F) Quantification of Polq localization at laser micro-irradiation sites in HeLa cells transfected with GFP-tagged full-length Polq and with indicated siRNA. gH2AX
immunofluorescence serves as a marker of laser-induced DNA breaks. Representative images are shown.
(G) Quantification of baseline and damage (UV)-induced Polq foci in HeLa cells transfected with indicated siRNA is shown.
(H and I) Quantification of Polq foci (H) and CtIP foci (I) formation in FANCD2-deficient (PD20) cells expressing EV, WT, or K561R FANCD2 cDNA constructs.
Representative images are shown.
(J) EJ reporter assay in EJ2-U2OS cells expressing indicated cDNAs and transfected with Scr or 50 UTR-FANCD2 siRNA.
Data in (A), (B), and (F)–(J) representmean ±SEMover three independent experiments. Data in (A), (B), (F), (G), and (J) are displayed as relative to siScr-transfected
sample, whose value is set to 1, and were analyzed using Student’s t test. Data in (H) and (I) were analyzed using the chi-square test for trend in proportions.siFANCD2-mediated decrease in Polq and CtIP foci and their
localization to laser-induced DNA stripes. WT FANCD2, but not
K561R-FANCD2, complemented the cells (Figures 4H, 4I, andS4K). In parallel, to evaluate whether FANCD2 monoubiquitina-
tion is necessary for alt-EJ activity, we assessed the ability of
WT or K561R-FANCD2 to complement the siFANCD2-mediatedCell Reports 15, 2488–2499, June 14, 2016 2493
Figure 5. FANCD2Overexpression in BRCA1-
Mutated Breast Cell Line Confers Resistance
to PARPi
(A) Clonogenic formation assay of BRCA1-mutated
(MDA-MB-436) breast cell line expressing EV or
FANCD2 cDNA constructs treated with increasing
concentrations of PARPi. FANCD2 immunoblot
shows cDNA construct expression. Representative
images for clonogenic formation assays are shown.
Survival of each sample is expressed as percentage
relative to non-treated (PARPi, 0 mM).
(B) Quantification of baseline and damage (IR)-
induced RAD51 foci in HeLa and BRCA1-mutated
(MDA-MB436) cells expressing indicated cDNA.
Data are displayed as relative to unirradiated HeLa
cells.
(C) Schematic for the labeling of MDA-MB-436 cells
with IdU and CldU for fork degradation experiments.
Scatter dot plot for CldU to IdU ratio upon
HU treatment for BRCA1-mutated (MDA-MB-436)
breast cell line expressing indicated cDNA is shown.
Statistics were performed on n R 100 fibers per
condition and expressed as relative to EV that was
conventionally set to 1.
(D) Model for FANCD2 functions in BRCA1- and
BRCA2-deficient tumors. FANCD2 functions in HR
and alt-EJ repair pathways and also participates in
genomic maintenance by protecting fork stability.
Although all pathways function in cycling cells, HR is
the predominant pathway under normal conditions
and the alt-EJ pathway is thought to play only a
minor role (left panel). Inactivation of BRCA1 or
BRCA2 has no consequence on cell survival, but it
induces both the localization of FANCD2 to stalled
forks and the hyperactivation of the alt-EJ pathway (middle panel). As a consequence, loss of both BRCA1/2 and FANCD2 pathways induces cell death, defining a
synthetic lethal interaction between the BRCA and the FA pathways (right panel).
Data in (A)–(C) represent mean ± SEM over three independent experiments and were analyzed using Student’s t test.decrease in alt-EJ activity. WT FANCD2, but not K561R-
FANCD2, rescued the alt-EJ activity, suggesting that FANCD2-
Ub is required for alt-EJ (Figure 4J). Collectively, these data
show that FANCD2 monoubiquitination promotes alt-EJ at
damaged sites in a mechanism dependent on Polq and CtIP
recruitment.
Since a synthetic lethal relationship exists between BRCA1/2
and FANCD2 (Figure 2A) as well as between BRCA1/2 and
Polq (Ceccaldi et al., 2015; Mateos-Gomez et al., 2015), we eval-
uatedwhether also CtIP knockdown affected BRCA1/2-deficient
cells’ survival. Unlike FANCD2 depletion, CtIP depletion did not
reduce BRCA2-deficient (VU 423) cell survival (Figure S5A).
These data were recapitulated in isogenic pairs of BRCA1/2-pro-
ficient and deficient HeLa cells that were subjected to siRNA-
mediated FANCD2 or CtIP depletion and assessed for clono-
genic survival (Figure S5B). All together, our data support a
role for FANCD2 as an upstream alt-EJ regulatory factor required
for both CtIP and Polq recruitment to damage sites and for
BRCA1/2-deficient cell survival.
FANCD2 Overexpression Confers Resistance to PARPis
through Replication Fork Stabilization
In BRCA1/2-deficient tumors, reduction of genomic instability
results in resistance to PARPis (Bouwman and Jonkers, 2014;
Lord and Ashworth, 2013). Since FANCD2 enables BRCA1/2-2494 Cell Reports 15, 2488–2499, June 14, 2016deficient cell survival, we determined whether FANCD2 overex-
pression could confer resistance to PARPis. We assessed
the clonogenic survival of BRCA1- and BRCA2-mutated cells
(MDA-MB-436 and VU 423, respectively) overexpressing WT or
K561R-FANCD2 cDNAs and grown in the presence of PARPi.
Overexpression of WT, but not K561R-FANCD2, increased the
PARPi resistance of BRCA1/2-mutated cells (Figures 5A and
S5C). Restoration of HR functionality represents the most com-
mon acquired mechanism of PARPi resistance in BRCA1/2-defi-
cient tumors (Edwards et al., 2008; Sakai et al., 2008). We thus
assessed whether FANCD2 overexpression restored HR in
BRCA1-mutated (MDA-MB-436) cells. Neither WT nor K561R-
FANCD2 improved HR function as measured by ionizing radia-
tion (IR)-induced RAD51 foci formation (Figure 5B), suggesting
that FANCD2-mediated PARPi resistance occurs independently
of HR restoration.
Given that FANCD2-Ub stabilizes replication forks in BRCA1/
2-deficient cells (Figure 1E), we tested whether the FANCD2-
mediated PARPi resistance correlated with increased fork pro-
tection. Of note,WT, but not K561R-FANCD2, improved fork sta-
bilization in BRCA1-mutated (MDA-MB-436) cells, as measured
by fork degradation after HU exposure (Figure 5C). Accordingly,
in BRCA1/2-deficient cells, increased FANCD2-Ub represents a
mechanism of PARPi resistance mediated by replication fork
protection.
DISCUSSION
The ability to stabilize and restart stalled replication forks is
essential to maintaining genomic stability and cell survival. The
importance of this survival mechanism is even more pronounced
in cancer cells, characterized by increased replication stress
levels (Bartkova et al., 2005; Gorgoulis et al., 2005). BRCA1/2
and FA proteins are known to cooperate in the repair of DNA le-
sions, causing replication stalling such as ICLs, by promoting
end resection and HR (Garcia-Higuera et al., 2001; Wang et al.,
2004). In the context of replication stress, BRCA1/2 and FA pro-
teins also cooperate in the protection of stalled replication forks
by limiting the endonuclease-dependent degradation of nascent
DNA strands (Schlacher et al., 2011, 2012). Besides cooperating
with BRCA1/2, FANCD2 also cooperates with BLM and FAN1 to
promote fork recovery (Chaudhury et al., 2013, 2014; Lachaud
et al., 2016).
BRCA1/2mutations, andotherHRgenemutations, are found in
a largeproportion of ovarianandbreast cancers (CancerGenome
Atlas Network, 2012; Cancer Genome Atlas Research Network,
2011). Importantly, these tumors are characterized by high levels
of replication stress (Cancer Genome Atlas Research Network,
2011; Pathania et al., 2014; Schlacher et al., 2011; Zeman and
Cimprich, 2014). Elevated replication stress renders these tumors
hyperdependent on additional protectivemechanisms that might
reduce the stress, thus promoting tumor cell survival.
To identify new survival mechanisms of BRCA1/2-deficient
cancers, we analyzed gene expression profiles in subsets of tu-
mors frequently associated with defects in HR. FANCD2 mRNA
and protein were specifically overexpressed in BRCA1- and
BRCA2-mutated ovarian and breast tumors, compared to HR-
proficient cancers. While FANCD2 normally functions epistati-
cally with BRCA1/2 to promote repair of ICL lesions (Figure 5D,
left panel), these results reveal a nonepistatic function of
FANCD2 and BRCA1/2 proteins in fork stabilization. Indeed, in
the case of tumors defective in HR (BRCA1/2 mutated), FANCD2
localizes at sites of stalled replication and is monoubiquitinated
(FANCD2-Ub) to a higher extent. Moreover, the upregulation of
FANCD2-Ub at stalled forks prevents fork degradation and facil-
itates fork restart (Figure 5D, middle panel). These results are
consistent with previous studies that show that FANCD2 has a
role in fork stabilization (Lossaint et al., 2013; Schlacher et al.,
2012) and fork restart by cooperating with the BLM helicase
(Chaudhury et al., 2013; Lossaint et al., 2013). Concomitant
with replication fork stabilization, FANCD2 mediates the survival
of BRCA1/2-mutated tumors by counteracting the onset of
genome instability events. These events arise from the collapse
or the instability of stalled forks. Indeed, loss of FANCD2 in
BRCA1/2-deficient cells hinders the stability of stalled replication
forks and causes severe and disabling damage that compro-
mises genomic integrity and cell survival. These findings reveal
a mechanism of synthetic lethality between BRCA1/2 and
FANCD2 (Figure 5D, right panel). Of note, the survival depen-
dency of BRCA1/2-mutated cancers on FANCD2 is displayed
in a large panel of breast and ovarian cancer cell lines and in
in vivo models of breast tumor xenografts.
While our results reveal a requirement for FANCD2-mediated
stabilization and restart of replication forks in BRCA1/2-deficientcells, the mechanism by which these cells repair stalled forks
also was examined. FANCD2 was required for Polq and CtIP
recruitment to damaged sites in order to promote alt-EJ (Fig-
ure 5D, middle panel). Alt-EJ is a highly error-prone DNA repair
pathway, requiring CtIP-mediated end resection and PARP1/
Polq-mediated microhomology-based repair (Kent et al., 2015;
Lee-Theilen et al., 2011; Simsek and Jasin, 2010; Wang et al.,
2006; Zhang and Jasin, 2011). While alt-EJ is a backup pathway
for the repair of DSBs in cells deficient for classical non-homol-
ogous EJ (C-NHEJ), it has emerged recently as an integral
DSB repair pathway contributing to the survival of HR-deficient
cancer cells (Aparicio et al., 2014; Bunting and Nussenzweig,
2013; Ceccaldi et al., 2015; Deriano andRoth, 2013;Mateos-Go-
mez et al., 2015).
Usually relying on HR for error-free repair (Couch et al., 2013),
stalled forks also are repaired through mutagenic pathways,
such as C-NHEJ or alt-EJ itself in the absence of HR (Ceccaldi
et al., 2016). This hypothesis is supported by evidence for a
direct role of PARP1 in fork stabilization and recovery after repli-
cative stress (Bryant et al., 2009; Ying et al., 2012, 2016). In this
study, we show that FANCD2 also acts as an alt-EJ factor.
Indeed, FANCD2 colocalizes with CtIP and Polq at bona fide
DNA damage sites and promotes microhomology-mediated
DNA repair in a GFP-based cell reporter system for alt-EJ, similar
to PARP1 and Polq. We next investigated the role of FANCD2 in
alt-EJ by establishing a functional hierarchy among alt-EJ pro-
teins. FANCD2 precedes and mediates the binding of CtIP and
Polq to DNA damages sites. Interestingly, siRNA-mediated
CtIP depletion does not limit the number of FANCD2 and Polq
foci after damage, nor does it cause synthetic lethality in
BRCA1/2-deficient cells. These data are in accordance with pre-
vious studies on the mutual contributions of CtIP and FANCD2 in
the control of fork recovery (Yeo et al., 2014). They also support
the hypothesis of a specific role for FANCD2 in fork protection
and ultimately the survival of HR-deficient cells.
While BRCA1 and BRCA2 proteins harbor distinct functions in
HR-mediated repair (Prakash et al., 2015), their deficiency simi-
larly leads to fork instability and high replicative stress (Pathania
et al., 2014; Schlacher et al., 2011). Moreover, FANCD2 is anal-
ogously upregulated in BRCA1- and BRCA2-deficient tumors.
For these reasons, we examined the role of FANCD2 upon loss
of BRCA1 or BRCA2 as a whole. Previous data showed that
BRCA1 was required for FANCD2 activation. For instance, loss
of BRCA1 leads to a decrease in IR-dependent induction of
FANCD2 foci (Bunting et al., 2012; Duquette et al., 2012; Gar-
cia-Higuera et al., 2001), and, in Xenopus egg extracts, BRCA1
is required for FANCD2 recruitment to a site-specific ICL (Long
et al., 2014). Nevertheless, BRCA1-deficient cells retain the abil-
ity to form distinct FANCD2 foci (Garcia-Higuera et al., 2001),
and the loss of BRCA1 increases the level of FANCD2-Ub.
Importantly, these data suggest that, even in the absence of
functional BRCA1, FANCD2-Ub is still loaded onto chromatin.
While FANCD2 is required for the survival of BRCA1-deficient
cells independently of the established BRCA1 role in activating
FANCD2, further studies should address whether BRCA1 is up-
stream or downstream of FANCD2. A possibility could be that
FANCD2 and BRCA1 present different functional interdepen-
dencies based on the genome stability pathway taken intoCell Reports 15, 2488–2499, June 14, 2016 2495
consideration. For instance, while BRCA1 seems to function up-
stream of FANCD2 in ICL repair (Long et al., 2014), our data sug-
gest that, in fork protection, FANCD2 functions upstream of
BRCA1.
Overall, our study demonstrates a dependency of HR-defi-
cient tumors on FANCD2 for cellular survival. In accordance
with previous studies (Ceccaldi et al., 2015; Mateos-Gomez
et al., 2015), survival of HR-deficient tumors is promoted by
mutagenic alt-EJ DNA repair pathways, of which FANCD2 is
identified as an upstream component. Moreover, we propose
that the dependency on FANCD2 of these tumors is mediated
by its fork stability and recovery functions. In contrast with the
common view where BRCA1/2 and FA proteins cooperate in
the repair of DNA lesions by HR, we here present evidence for
a compensatory fork stabilization activity of FANCD2 in the
absence of BRCA1/2 proteins. Aware of the limitations of the ge-
netic, repair-deficient context that we have investigated, we
believe that characterizing the role of FANCD2 and its partners
in fork protection might shed light on the unexplored mecha-
nisms of fork stabilization as a widespread mechanism of tumor
cell survival. More broadly, it will be of interest to investigate
whether FANCD2 represents a fork stabilization and/or a survival
factor only in BRCA1/2-mutated cancers or also in other cancers
that are characterized by high replication stress levels, for
example, as a consequence of oncogene activation.
Other questions remain to be answered, such aswhether an in-
verse compensatory mechanism exists between the BRCA1/2
and FA proteins where BRCA1/2 proteins could compensate for
FA pathway deficiency, as in the case of FA patients. Further
studies also should aim to understand in greater depth what
aspect ofFANCD2 (fork stabilizationoralt-EJ repair) is responsible
for the survival of BRCA1/2-deficient tumors. In this regard, our
data indicate that FANCI depletion induces synthetic lethality in
BRCA1/2-deficient cells, similar to FANCD2 depletion. Since
FANCI recently was shown to promote fork restart upon replica-
tion stress (Chen et al., 2015), our results enforce the hypothesis
that the forkprotection functionof FApathwaymembers is amajor
regulator of BRCA1/2-deficient cells survival. In addition, while
previous studies on Polq suggest that the alt-EJ pathway is
required for BRCA1/2 survival (Ceccaldi et al., 2015; Mateos-Go-
mezetal., 2015), this is not thecase for other alt-EJ factors suchas
CtIP, whose depletion, while decreasing alt-EJ efficiency, does
not confer synthetic lethalitywithBRCA1/2deficiency. Clinical ap-
plications relying on synthetic lethality relationships are just begin-
ning to emerge, and understanding these relationships can shed
light on unexpected connections between biological pathways.
Therefore, it is of critical importance to dissect their molecular ba-
sis from both basic and translational perspectives.EXPERIMENTAL PROCEDURES
Bioinformatic Analysis
The Cancer Genome Atlas (TCGA) datasets were accessed through the public
TCGAdata portal (https://tcga-data.nci.nih.gov/tcga/). Formutation count, we
accessed data from tumors included in the TCGA datasets for which gene
expression and whole-exome DNA sequencing were available. Data were
accessed through the public TCGA data portal and the cBioPortal for Cancer
Genomics (http://www.cbioportal.org). For each TCGA dataset, non-synony-
mous mutation count was assessed in tumors with high FANCD2 expression2496 Cell Reports 15, 2488–2499, June 14, 2016(top 50%) and compared to tumors with low FANCD2 expression (the remain-
ing 50%). In the uterine TCGA, we curated all tumors except the ultra and hy-
per-mutated group (that is, POLE and MSI tumors). In the ovarian and breast
TCGA datasets, all tumors were analyzed. FANCD2 expression analysis
shown in Figure S1C was extracted from the ovarian serous carcinoma data-
sets (GEO: GSE14001, GSE14007, GSE18520, GSE16708, and GSE10971)
and compared to the ovarian clear cell carcinoma dataset (GEO: GSE29450).
Immunoblot Analysis, Cellular Fractionation, and
Immunofluorescence
Cells were lysed with 1% NP40 lysis buffer (1% NP40, 300 mM NaCl, 0.1 mM
EDTA, and 50 mM Tris [pH 7.5]) supplemented with protease inhibitor cocktail
(Roche), resolved by NuPAGE (Invitrogen) gels and transferred onto nitrocellu-
lose membrane, followed by detection using the LAS-4000 Imaging system
(GE Healthcare Life Sciences). For cellular fractionation, cells were incubated
with low-salt permeabilization buffer (10 mM Tris [pH 7.3], 10 mM KCl, and
1.5 mMMgCl2) with protease inhibitor on ice for 20 min. Following centrifuga-
tion, nuclei were resuspended in 0.2 M HCl and the soluble fraction was
neutralized with 1 M Tris-HCl (pH 8.0). Nuclei were lysed in 150 mM NaCl,
and, following centrifugation, the chromatin pellet was digested by micro-
coccal nuclease (Roche) for 5 min at room temperature. See the Supplemental
Experimental Procedures for details on immunofluorescence procedures.
Antibodies, Chemicals, Plasmids, and Transfection
Antibodies used in this study included the following: anti-FANCD2 (FI-17, for
immunoblotting), anti-histone H3 (FL-136), anti-PCNA (PC-10), anti-TopBP1
(B-7), anti-vinculin (H-10), and anti-RAD51 (H-92) (all from Santa Cruz Biotech-
nology); anti-BRCA1 and anti-BRCA2 (both Ab-1, Calbiochem); anti-FANCD2
(NB100-182, for immunofluorescence, Novus Biologicals); anti-phospho-His-
tone-H2AX (p-Ser139) (05-636, EMD Millipore and 2572, Cell Signaling Tech-
nology); and anti-CtIP (14-1, Active Motif). MMC and HU were purchased from
Sigma. See the Supplemental Experimental Procedures for details on siRNAs,
shRNAs, and plasmids.
Cell Culture
HeLa, U2OS, VU 423 (BRCA2/), PD20 (FANCD2/), and PD20-corrected
cells were maintained in DMEM plus 10% fetal calf serum (FCS), L-glutamine
(2 mM), and penicillin-streptomycin (1%). MDA-MB-436 (BRCA1-mutated)
cells were maintained in RPMI medium plus 10% FCS, L-glutamine (2 mM),
and penicillin-streptomycin (1%). Breast and ovarian cell lines used in the Fig-
ures 3A and S3A were cultured according to recommendations present in the
literature (Table S1). HR, alt-EJ, and SSA efficiencies were measured using
U2OS cell line expressing the DR-GFP (HR efficiency), EJ2-GFP (alt-EJ effi-
ciency), and SA-GFP (SSA efficiency) reporter assay and performed as previ-
ously described (Bennardo et al., 2008; Nakanishi et al., 2005).
Cell Survival Assays
To assess clonogenic survival, cells were transfected twice with the indicated
siRNAs for 48 hr, then harvested and seeded at low density into six-well plates
in triplicates. For clonogenic survival under MMC or PARPi (rucaparib), cells
were treated continuously with the indicated drug concentrations. Survival at
each drug concentration was plotted as a percentage relative to the survival
in drug-free media. Colony formation was scored 14 days after drug treatment
or siRNA transfection using 0.5% (w/v) crystal violet in methanol. Survival
curves were expressed as a percentage ±SEM over three independent exper-
iments and relative to control cells (siScr). MMC was purchased from Sigma
while the PARPi rucaparib (AG-014699) was purchased from Selleckchem.
Chromosomal Breakage Analysis
A2780 expressing the indicated shRNAs and VU 423 cells twice transfected
with the indicated siRNAs were incubated for 48 hr with or without the indi-
cated concentrations of MMC. Cells were exposed for 2 hr to 100 ng/ml colce-
mid, treated with a hypotonic solution (0.075 M KCl) for 20 min, and fixed with
3:1 methanol/acetic acid. Slides were stained withWright’s stain and 50 meta-
phase spreads were scored for aberrations. The relative number of chromo-
somal breaks and radials was calculated relative to control cells (siScr) or
shBRCA2, as indicated in the figure legends.
FANCD2 Gene Expression
RNA samples extracted using the TRIzol Reagent (Invitrogen) were reverse
transcribed using the Transcriptor Reverse Transcriptaze kit (Roche) and oligo
dT primers. The resulting cDNA was used to analyze FANCD2 expression by
qRT-PCR using the QuantiTect SYBRGreen kit (QIAGEN) in an iCycler ma-
chine (Bio-Rad). FANCD2 gene expression values were normalized to expres-
sion of the housekeeping geneGAPDH, using the DCt method, and are shown
on a log2 scale. See the Supplemental Experimental Procedures for details on
primers and the FANCD2 expression data shown in Figure 3A.
DNA Fiber Analysis
For the fork degradation analysis, PD20 cells expressing empty vector (EV),
WT FANCD2, or K561R-FANCD2 were incubated with 250 mM iododeoxyuri-
dine (IdU) (Sigma, I7125) for 30 min, followed by 25 mM chlorodeoxyuridine
(CldU) (Sigma, C6891) for 30 min. Cells were then incubated with 4 mM HU
for 2.5 hr. For the fork restart analysis, cells were incubated with 250 mM IdU
for 30 min. Cells were then treated with 1 mM HU for 1 hr and incubated in
25 mM CldU for 30 min after washout of the drug. Spreading of DNA fibers
on glass slides was done as previously reported (Jackson and Pombo,
1998). Glass slides were then washed in distilled water and in 2.5 M HCl for
120 min followed by three washes in PBS. The slides were incubated for
1 hr in blocking buffer (PBS with 1% BSA) and then for 1 hr at 37C in rat
anti-BrdU antibody (Abcam, ab6326) and mouse anti-BrdU antibody (BD Bio-
sciences, 347580) diluted in blocking buffer. After washes in PBS, the slides
were incubated for 1 hr at 37C in goat anti-rat Alexa 488 antibody (Life Tech-
nologies, A-11006) and chicken anti-mouse Alexa 594 (Life Technologies,
A-21201) diluted in blocking buffer. The slides were then washed with PBS
and mounted with DAPI. At least 100 fibers were counted per condition. Pic-
tures were taken with an Olympus confocal microscope and fiber length was
measured by ImageJ software.
Studies of Xenograft-Bearing CrTac:NCr-Foxn1nu Mice
In vivo studies were performed as previously described (Ceccaldi et al., 2015),
under approval of the Animal Resource Facility at the Dana-Farber Cancer
Institute. See the Supplemental Experimental Procedures for more details.
Statistical Analysis
Data are represented as mean ±SEM over three independent experiments.
Unless otherwise stated, significance was calculated using the unpaired Stu-
dent’s t test or the chi-square test for trend in proportions. Analyses were per-
formed by the use of GraphPad Prism 6 software. A p value less than 0.05 was
considered statistically significant (ns, not significant; *p < 0.05, **p < 0.01, and
***p < 0.001). All the in vivo experiments were run with at least ten tumors from
six mice for each condition.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and one table and can be found with this article online at http://
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